Sotera Health Company (SHC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial metrics, including raised revenue and EBITDA growth outlooks, improved net leverage ratio, and increased adjusted EPS guidance. Despite some concerns, such as margin compression and Q4 pullback, the overall sentiment is positive, with consistent performance across key areas and confidence in long-term growth. The market cap suggests moderate volatility, leading to a positive stock price prediction (2%-8%) over the next two weeks.
Key Financial Performance
Total company revenues $311 million, a 9.1% increase year-over-year (8% on a constant currency basis). The growth was driven by strong top-line performance across segments.
Adjusted EBITDA $164 million, a 12.2% increase year-over-year (11.2% on a constant currency basis). The increase was attributed to improved margins in Sterigenics and Nelson Labs.
Adjusted EBITDA margins 52.7%, an increase of 147 basis points year-over-year. This was driven by improved margins in both Sterigenics and Nelson Labs.
Interest expense $39 million, a $2.4 million improvement year-over-year. The improvement was due to debt repayment and lower interest rates.
Net income $48 million or $0.17 per diluted share, compared to $17 million or $0.06 per diluted share in Q3 2024. The increase was driven by adjusted EBITDA growth, lower interest expense, and a reduced tax rate.
Adjusted EPS $0.26, an increase of $0.09 year-over-year. The increase was driven by adjusted EBITDA growth, lower interest expense, and a reduced tax rate.
Sterigenics revenue $193 million, a 9.8% increase year-over-year (8.4% on a constant currency basis). Growth was driven by favorable volume mix (4.6%), increased pricing (3.8%), and a 140 basis point benefit from foreign currency exchange.
Sterigenics segment income $107 million, an 11.6% increase year-over-year (10.2% on a constant currency basis). Margins improved by 90 basis points to 55.6%, driven by strong top-line growth, partially offset by inflation.
Nordion revenue $63 million, a 22.4% increase year-over-year (23.6% on a constant currency basis). Growth was driven by volume and mix benefits (18.9%) and favorable pricing (4.7%), partially offset by a 120 basis point unfavorable impact from foreign currency exchange rates.
Nordion segment income $38 million, a 19.9% increase year-over-year (21.2% on a constant currency basis). Growth was driven by increased volume and mix as well as customer pricing. Margins decreased by 130 basis points to 60.6%, driven by product mix.
Nelson Labs revenue $56 million, a 5% decline year-over-year. Growth in core lab testing and favorable pricing (2.7%) were offset by a decline in Expert Advisory Services.
Nelson Labs segment income $19 million, a 1.9% increase year-over-year (flat on a constant currency basis). Margins expanded by 229 basis points to 34.1%, driven by volume and mix improvements, lab optimization, and favorable pricing.
Operating cash flow $184 million year-to-date. This reflects strong cash generation.
Capital expenditures $87 million year-to-date. This reflects ongoing investments in the business.
Available liquidity Over $890 million, including $300 million in unrestricted cash and $600 million in available capacity on a revolving line of credit.
Net leverage ratio 3.3x at quarter-end, down from 3.7x at the end of 2024 and 4.2x at the end of Q3 2023. The improvement was driven by debt repayment and adjusted EBITDA growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nordion's 25-year license renewal: Nordion secured a 25-year renewal of its Class 1B operating license, the longest ever granted by the Canadian Nuclear Safety Commission. This ensures a reliable supply of Cobalt-60 for sterilization and radiotherapeutic treatments.
Revenue growth: Total company revenues increased by 9.1% in Q3 2025 compared to Q3 2024. Sterigenics achieved 9.8% growth, Nordion 22.4%, while Nelson Labs saw a 5% decline.
Debt reduction and interest savings: The company paid down $75 million in debt, reducing annual interest expenses by $13 million.
Operational improvements: Nelson Labs achieved margin expansion for the fifth consecutive quarter, driven by core lab testing growth and operational enhancements.
Legal updates on ethylene oxide claims: The Georgia Court of Appeals rejected a trial court's 'new standard' for causation in ethylene oxide cases, aligning with the company's position. Three bellwether cases were dismissed due to lack of reliable evidence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Nelson Labs Revenue Decline: Nelson Labs reported a 5% decline in revenue for Q3 2025 compared to the same period last year, driven by a decline in Expert Advisory Services, which offset growth in core lab testing and improved pricing. This poses a challenge to the segment's overall performance.
Inflation Impact on Margins: Inflation partially offset the strong top-line growth in the Sterigenics segment, which could impact profitability if inflationary pressures persist.
Ethylene Oxide (EO) Litigation: The company is facing ongoing litigation related to ethylene oxide emissions in Cobb County, Georgia. While recent rulings have been favorable, the legal process is lengthy and could result in financial and reputational risks.
Product Mix Impact on Margins: Nordion's segment income margin decreased by approximately 130 basis points due to product mix, which could affect profitability if unfavorable product mix trends continue.
Decline in Expert Advisory Services: The decline in Expert Advisory Services within Nelson Labs is a specific challenge, as it offsets gains in other areas like core lab testing and pricing.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Revenue Growth Outlook: Maintaining full year constant currency revenue growth outlook range of 4.5% to 6%, with revenue growth expected near the midpoint of this range.
2025 Adjusted EBITDA Growth Outlook: Raising constant currency adjusted EBITDA growth outlook to 6.75% to 7.75%, up from the prior range of 6% to 7.5%. Foreign currency expected to contribute approximately 25 basis points to revenue and adjusted EBITDA growth.
Sterigenics 2025 Revenue Growth: Expecting constant currency revenue growth of mid- to high single digits.
Nordion 2025 Revenue Growth: Raised full year constant currency revenue growth outlook to mid- to high single-digit growth. No longer any revenue risk associated with Cobalt-60 for 2025.
Nelson Labs 2025 Revenue Outlook: Expecting full year constant currency revenues to decline mid-single digits due to impact from Expert Advisory Services, despite growth in core lab testing and improved pricing. Segment income margin expected to finish in the low to mid-30% range for the full year.
Interest Expense Outlook: Improved interest expense range to $154 million to $158 million, down from the previous outlook of $155 million to $165 million.
Effective Tax Rate on Adjusted Net Income: Expected to be in the range of 29% to 31%, improving from the prior range of 31.5% to 33.5%.
Adjusted EPS Outlook: Expected to be in the range of $0.81 to $0.86, an increase from the previous range of $0.75 to $0.82.
Capital Expenditures Outlook: Expected to be in the range of $125 million to $135 million, below the prior outlook of $170 million to $180 million, driven by project timing and incremental cost savings. Cumulative capital expenditures from 2025 through 2027 remain unchanged.
Free Cash Flow Commitment: On track to achieve $500 million to $600 million cumulative free cash flow commitment provided at the 2024 Investor Day.
Net Leverage Ratio: Year-end 2025 net leverage ratio expected to improve compared to 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there certain areas you are seeing outsized volume recovery, particularly in MedTech and bioproduction?
A:Michael Petras stated that they are seeing consistent performance across Sterigenics and almost all categories, including bioprocessing and MedTech broadly. He noted good recovery in volumes and expects this trend to continue.
Q:Can you provide an update on the litigation cases?
A:Michael Petras provided updates on various cases: Illinois is wrapping up with an April 2025 settlement completed, leaving only one remaining case. In Georgia, updates were given earlier. In New Mexico, there are no personal injury claims, only one public nuisance suit set for trial in July 2026. In California, the first trials are expected in January and April 2027.
Q:Are you factoring in any expectation of a budget flush in 4Q, and how conservative is your guidance for 2025?
A:Michael Petras clarified that they are not expecting a budget flush from MedTech or bioprocessing customers. He stated that their guidance for the rest of the year is confident, neither aggressive nor conservative.
Q:Are you seeing any impact from the government shutdown in your RCA business or elsewhere?
A:Michael Petras mentioned that there is no direct government sales in their business, and the indirect impact is minimal. There is some effect on Expert Advisory Services due to delays, but overall, it is not material.
Q:What is causing the worsening in the Expert Advisory business, and what is the reason for the implied 4Q EBITDA margin step down?
A:Michael Petras attributed the worsening in Expert Advisory Services to the FDA's lack of activity, which had a 10-point impact on the top line. Jonathan Lyons added that Q4 margins are expected to step back slightly due to lower expenses in Q3 and stable margins for the year.
Q:What is the balance between Expert Advisory headwinds and core lab testing demand?
A:Michael Petras stated that core lab testing is doing well, with routine volumes picking up and Embedded Labs growth continuing. However, validation has been choppy, and they would like to see better growth overall.
Q:Why is there a sequential revenue and margin pullback in Q4 compared to Q3?
A:Michael Petras explained that the pullback is due to Nordion's lumpiness, with some revenue pulled into Q3 from customer requests. Overall, Nordion is expected to be above expectations for the year.
Q:What type of mix shift in Nordion caused margin compression, and will it persist?
A:Michael Petras clarified that the margin compression was due to growth in lower-margin product sales, particularly radiators equipment sales. He stated that this is sporadic and not a material long-term impact.
Q:How sustainable is the mid- to high single-digit growth in Sterigenics, and are there any key moving pieces for next year?
A:Michael Petras reiterated their long-range guidance of mid- to high single-digit growth for Sterigenics and stated that they feel confident about their long-range commitments. Guidance for next year will be provided later.
Q:Where do you think Sterigenics pricing contribution stabilizes, and are there opportunities for stronger pricing?
A:Michael Petras stated that Sterigenics pricing is expected to remain at the high end of the 3%-4% range. He mentioned potential additional pricing opportunities related to NESHAP regulations.
Q:Is the NESHAP-related pricing opportunity more of a post-2026 event, and how many cases are there in California?
A:Michael Petras indicated that NESHAP-related pricing improvements will build gradually over time and provided guidance for future years. He also mentioned that there are 83 personal injury claims in California.
Q:Is it reasonable to expect Nelson to return to growth in 2026 given the advisory headwinds?
A:Michael Petras agreed that it is logical to expect Nelson to return to growth in 2026, though formal guidance was not provided.
Q:Was there any pull-forward of ordering for MedTech customers ahead of tariffs?
A:Michael Petras stated that there was minimal impact from pull-forward ordering, with only a few last-minute requirements from customers, which were not material.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer when asked about the sustainability of Sterigenics pricing contributions and the timeline for NESHAP-related pricing opportunities. While they provided general comments, they did not offer specific details or clarity on these topics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisory Services
CNSC conference
Canadian Nuclear
Class Ib
Class license
Cobalt currency
Cobalt health
Cobalt sterilization
Commission milestone
Conference event
Day end
Expert Advisory
Investors section
Nordion currency
Sotera Health
addition
basis Nordion
benefit
currency outlook
date
debt
expectation
health care
income currency
increase
interest expense
lab testing
margin expansion
outlook currency
point reduction
pricing basis
saving
sheet interest
supply Cobalt
term loan
SHC Transcript
Sotera Health Company (SHC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Sotera Health Company (SHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Sotera Health Company (SHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral5-19
Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary presents a mixed picture. Financial performance is stable with slight growth, but there is a cautious tone in guidance and potential regulatory impacts. The Q&A reveals some concerns about growth slowdowns and regulatory changes, but also highlights operational resilience and customer satisfaction. The market cap suggests moderate sensitivity to these factors, leading to a neutral prediction for stock movement.
SHC Slides
Sotera Health Q1 2026 slides: earnings beat amid segment divergence2026-05-05
Sotera Health Q4 2025 slides: 20th year of growth, margins hit 51%2026-02-24
Sotera Health Q3 2025 slides: Revenue jumps 9.1%, company raises full-year guidance2025-11-04
Sotera Health Q2 2025 slides: revenue growth accelerates, EBITDA margins expand2025-08-08
SHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
